Abstract
Current protocols for chondrocyte expansion and chondrogenic differentiation of stem cells fail to reduce phenotypic loss and to mitigate hypertrophic tendency. To this end, cell genetic manipulation is gaining pace as a means of generating cells with stable chondrocyte phenotype. Herein, we provide an overview of candidate genes that either induce cartilage regeneration or inhibit cartilage degeneration. We further discuss in vitro, ex vivo and in vivo viral transduction and non-viral transfection strategies for targeted cells (chondrocytes, mesenchymal stem cells, induced pluripotent stem cells and synovial cells), along with the most representative results obtained in pre-clinical models and in clinical trials. We highlight current challenges and associated risks that slowdown clinical acceptance and commercialisation of gene transfer technologies.
| Original language | English (US) |
|---|---|
| Journal | Biotechnology Advances |
| DOIs | |
| State | Accepted/In press - Jan 1 2018 |
Fingerprint
Keywords
- Cartilage tissue engineering
- Gene engineering
- Genetically engineered cells
- Non-viral transfection systems
- Viral transduction systems
ASJC Scopus subject areas
- Biotechnology
Cite this
State of art and limitations in genetic engineering to induce stable chondrogenic phenotype. / Graceffa, Valeria; Vinatier, Claire; Guicheux, Jerome; Evans, Christopher H; Stoddart, Martin; Alini, Mauro; Zeugolis, Dimitrios I.
In: Biotechnology Advances, 01.01.2018.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - State of art and limitations in genetic engineering to induce stable chondrogenic phenotype
AU - Graceffa, Valeria
AU - Vinatier, Claire
AU - Guicheux, Jerome
AU - Evans, Christopher H
AU - Stoddart, Martin
AU - Alini, Mauro
AU - Zeugolis, Dimitrios I.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Current protocols for chondrocyte expansion and chondrogenic differentiation of stem cells fail to reduce phenotypic loss and to mitigate hypertrophic tendency. To this end, cell genetic manipulation is gaining pace as a means of generating cells with stable chondrocyte phenotype. Herein, we provide an overview of candidate genes that either induce cartilage regeneration or inhibit cartilage degeneration. We further discuss in vitro, ex vivo and in vivo viral transduction and non-viral transfection strategies for targeted cells (chondrocytes, mesenchymal stem cells, induced pluripotent stem cells and synovial cells), along with the most representative results obtained in pre-clinical models and in clinical trials. We highlight current challenges and associated risks that slowdown clinical acceptance and commercialisation of gene transfer technologies.
AB - Current protocols for chondrocyte expansion and chondrogenic differentiation of stem cells fail to reduce phenotypic loss and to mitigate hypertrophic tendency. To this end, cell genetic manipulation is gaining pace as a means of generating cells with stable chondrocyte phenotype. Herein, we provide an overview of candidate genes that either induce cartilage regeneration or inhibit cartilage degeneration. We further discuss in vitro, ex vivo and in vivo viral transduction and non-viral transfection strategies for targeted cells (chondrocytes, mesenchymal stem cells, induced pluripotent stem cells and synovial cells), along with the most representative results obtained in pre-clinical models and in clinical trials. We highlight current challenges and associated risks that slowdown clinical acceptance and commercialisation of gene transfer technologies.
KW - Cartilage tissue engineering
KW - Gene engineering
KW - Genetically engineered cells
KW - Non-viral transfection systems
KW - Viral transduction systems
UR - http://www.scopus.com/inward/record.url?scp=85050091939&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050091939&partnerID=8YFLogxK
U2 - 10.1016/j.biotechadv.2018.07.004
DO - 10.1016/j.biotechadv.2018.07.004
M3 - Article
JO - Biotechnology Advances
JF - Biotechnology Advances
SN - 0734-9750
ER -